AimedBio and Boehringer Ingelheim Start Phase I Study of BI 4060107
AimedBio and Boehringer Ingelheim initiated a Phase I study of antibody-drug conjugate BI 4060107.
AimedBio and Boehringer Ingelheim initiated a Phase I study of antibody-drug conjugate BI 4060107.